Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 701

1.

Predicting the impact of Lynch syndrome-causing missense mutations from structural calculations.

Nielsen SV, Stein A, Dinitzen AB, Papaleo E, Tatham MH, Poulsen EG, Kassem MM, Rasmussen LJ, Lindorff-Larsen K, Hartmann-Petersen R.

PLoS Genet. 2017 Apr 19;13(4):e1006739. doi: 10.1371/journal.pgen.1006739. eCollection 2017 Apr.

2.

Overexpression of MutSα Complex Proteins Predicts Poor Prognosis in Oral Squamous Cell Carcinoma.

Wagner VP, Webber LP, Salvadori G, Meurer L, Fonseca FP, Castilho RM, Squarize CH, Vargas PA, Martins MD.

Medicine (Baltimore). 2016 May;95(22):e3725. doi: 10.1097/MD.0000000000003725.

3.

Causes of Cancer Death Among First-Degree Relatives in Japanese Families with Lynch Syndrome.

Tanakaya K, Yamaguchi T, Ishikawa H, Hinoi T, Furukawa Y, Hirata K, Saida Y, Shimokawa M, Arai M, Matsubara N, Tomita N, Tamura K, Sugano K, Ishioka C, Yoshida T, Ishida H, Watanabe T, Sugihara K; for HNPCC Registry and Genetic Testing Project of the Japanese Society for Cancer of the Colon and Rectum.

Anticancer Res. 2016 Apr;36(4):1985-9.

PMID:
27069191
4.

Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants.

Houlleberghs H, Dekker M, Lantermans H, Kleinendorst R, Dubbink HJ, Hofstra RM, Verhoef S, Te Riele H.

Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):4128-33. doi: 10.1073/pnas.1520813113. Epub 2016 Mar 7.

5.

A cryptic paracentric inversion of MSH2 exons 2-6 causes Lynch syndrome.

Liu Q, Hesson LB, Nunez AC, Packham D, Williams R, Ward RL, Sloane MA.

Carcinogenesis. 2016 Jan;37(1):10-17. doi: 10.1093/carcin/bgv154. Epub 2015 Oct 24.

PMID:
26498247
6.

MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers.

Maresca L, Spugnesi L, Lodovichi S, Cozzani C, Naccarato AG, Tancredi M, Collavoli A, Falaschi E, Rossetti E, Aretini P, Cervelli T, Galli A, Caligo MA.

Eur J Med Genet. 2015 Oct;58(10):531-9. doi: 10.1016/j.ejmg.2015.09.005. Epub 2015 Sep 14.

PMID:
26381082
7.

Family with MSH2 mutation presenting with keratoacanthoma and precancerous skin lesions.

Hatta N, Takata A, Ishizawa S, Niida Y.

J Dermatol. 2015 Nov;42(11):1087-90. doi: 10.1111/1346-8138.12949. Epub 2015 Jun 16.

PMID:
26077460
8.

Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.

McFaline-Figueroa JL, Braun CJ, Stanciu M, Nagel ZD, Mazzucato P, Sangaraju D, Cerniauskas E, Barford K, Vargas A, Chen Y, Tretyakova N, Lees JA, Hemann MT, White FM, Samson LD.

Cancer Res. 2015 Aug 1;75(15):3127-38. doi: 10.1158/0008-5472.CAN-14-3616. Epub 2015 May 29.

9.

[Lynch syndrome and risk of prostate cancer; review of the literature].

Maillard F, Manouvrier S, Biardeau X, Ouzzane A, Villers A.

Prog Urol. 2015 Apr;25(5):225-32. doi: 10.1016/j.purol.2015.01.001. Epub 2015 Jan 29. Review. French.

PMID:
25640028
10.

Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells.

Ko JC, Chiu HC, Syu JJ, Chen CY, Jian YT, Huang YJ, Wo TY, Jian YJ, Chang PY, Wang TJ, Lin YW.

Biochem Biophys Res Commun. 2015 Jan 2;456(1):506-12. doi: 10.1016/j.bbrc.2014.11.116. Epub 2014 Dec 6.

PMID:
25490383
11.

Characterization of complementary determinant region 3δ in human MutS homologue 2-specific γδ T cells.

Chen H, Ji X, Cui L, Zhang J, He W.

Scand J Immunol. 2015 Feb;81(2):121-8. doi: 10.1111/sji.12256.

12.

hMSH2 expression is associated with paclitaxel resistance in ovarian carcinoma, and inhibition of hMSH2 expression in vitro restores paclitaxel sensitivity.

Zhang J, Yin D, Li H.

Oncol Rep. 2014 Nov;32(5):2199-206. doi: 10.3892/or.2014.3430. Epub 2014 Aug 20.

PMID:
25175513
13.

Gly322Asp and Asn127Ser single nucleotide polymorphisms (SNPs) of hMSH2 mismatch repair gene and the risk of triple-negative breast cancer in Polish women.

Smolarz B, Makowska M, Samulak D, Michalska MM, Romanowicz H.

Fam Cancer. 2015 Mar;14(1):81-8. doi: 10.1007/s10689-014-9746-z.

14.

Challenges in assessing pathogenicity based on frequency of variants in mismatch repair genes: an extreme case of a MSH2 variant and a meta-analysis.

Woo HI, Woo YM, Kim S, Lee ST, Ki CS, Kim JW.

Gene. 2014 Aug 10;546(2):421-4. doi: 10.1016/j.gene.2014.06.027. Epub 2014 Jun 14. Review.

PMID:
24933000
15.

Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.

Tung CL, Chiu HC, Jian YJ, Jian YT, Chen CY, Syu JJ, Wo TY, Huang YJ, Tseng SC, Lin YW.

Exp Cell Res. 2014 Apr 1;322(2):345-54. doi: 10.1016/j.yexcr.2014.02.002. Epub 2014 Feb 12.

PMID:
24530475
16.

Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.

Wielders EA, Hettinger J, Dekker R, Kets CM, Ligtenberg MJ, Mensenkamp AR, van den Ouweland AM, Prins J, Wagner A, Dinjens WN, Dubbink HJ, van Hest LP, Menko F, Hogervorst F, Verhoef S, te Riele H.

J Med Genet. 2014 Apr;51(4):245-53. doi: 10.1136/jmedgenet-2013-101987. Epub 2014 Feb 5.

PMID:
24501230
17.

Low expression of MSH2 DNA repair protein is associated with poor prognosis in head and neck squamous cell carcinoma.

Pereira CS, Oliveira MV, Barros LO, Bandeira GA, Santos SH, Basile JR, Guimarães AL, De Paula AM.

J Appl Oral Sci. 2013 Sep-Oct;21(5):416-21. doi: 10.1590/1679-775720130206.

18.

Frequency and variability of genomic rearrangements on MSH2 in Spanish Lynch Syndrome families.

Romero A, Garre P, Valentin O, Sanz J, Pérez-Segura P, Llovet P, Díaz-Rubio E, de la Hoya M, Caldés T.

PLoS One. 2013 Sep 11;8(9):e72195. doi: 10.1371/journal.pone.0072195. eCollection 2013.

19.

DNA mismatch repair protein MSH2 dictates cellular survival in response to low dose radiation in endometrial carcinoma cells.

Martin LM, Marples B, Davies AM, Atzberger A, Edwards C, Lynch TH, Hollywood D, Marignol L.

Cancer Lett. 2013 Jul 10;335(1):19-25. doi: 10.1016/j.canlet.2013.01.046. Epub 2013 Jan 31.

PMID:
23376256
20.

The MSH2 c.388_389del mutation shows a founder effect in Portuguese Lynch syndrome families.

Pinheiro M, Pinto C, Peixoto A, Veiga I, Mesquita B, Henrique R, Lopes P, Sousa O, Fragoso M, Dias LM, Baptista M, Marinho C, Mangold E, Vaccaro C, Evans DG, Farrington S, Dunlop MG, Teixeira MR.

Clin Genet. 2013 Sep;84(3):244-50. doi: 10.1111/cge.12062. Epub 2012 Dec 27.

PMID:
23170986

Supplemental Content

Support Center